Work Area: Trade secrets

Latest content

Pfizer acts quickly to tackle alleged covid-19 vaccine trade secrets misappropriation

With strong policies in place to protect confidential information, the company was able to take swift action against an employee after becoming aware of suspicious activity

25 November 2021

Talks over covid vaccine IP waiver appear increasingly futile

Saturday Opinion: The prospect of an international agreement on the proposed suspension of TRIPS now appears vanishingly small

23 October 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

What to know about Baosteel: the Chinese giant behind Japan’s biggest patent dispute

The state-owned firm has moved up the value chain despite its limited overseas patent holdings, but it is no stranger to high-stakes IP legal fights abroad

22 October 2021

Moderna’s covid-19 patent pledge may be backfiring

Though a short-term PR success, the company’s commitment risks looking hollow after its decision not to license know-how to new WHO Africa tech-transfer hub

15 October 2021

AbbVie suffers knock-back in Humira trade secrets dispute

Illinois district court dismisses case relating to alleged misappropriation outside the US

15 October 2021

Biopharma IP licensors are getting more money - and earlier - for their innovations

M&A may be stagnant, but innovators are receiving larger upfront payments for partnership agreements

01 October 2021

TSMC has catalogued more than 140,000 trade secrets since 2013, company says

Chipmaker has operated a trade secret registration system for eight years, and is now looking to shore up management practices among its suppliers

01 October 2021

Moderna’s covid-19 IP pledge is about to be put to the test

The WHO’s African vaccine hub is seeking to imitate the company’s jab, but an agreement has yet to be reached

24 September 2021

Why the delay in picking a new USPTO director really matters

Acting head Drew Hirshfeld says he’s focused on doing the best job possible, but some fear that without a permanent political appointee the agency could be hamstrung

03 September 2021

Get unlimited access to all IAM content